CVSI CV Sciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1510964 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-12.9%
TTM net income YoY-16.2%
TTM EPS YoY—
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—
Margins
Gross margin49.5%
Operating margin-2.5%
Net margin-13.7%
FCF margin-1.5%
EBITDA margin-1.8%
Returns
ROE-90.1%
ROA-25.6%
ROIC (approx.)-12.3%
Asset turnover1.86x
Leverage & solvency
Liabilities / assets64.7%
Debt / equity0.00x
Current ratio1.18x
Interest coverage-1.42x
Cash quality & payout
Operating cash flow / net income0.10x
Accruals ratio-23.0%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.79M | $15.71M |
| Cost of revenue | $7.04M | $8.54M |
| Gross profit | $6.75M | $7.17M |
| R&D expense | $122,000 | $118,000 |
| SG&A expense | $7.62M | $9.24M |
| Operating income | -$470,000 | -$2.19M |
| Interest expense | $517,000 | $212,000 |
| Pretax income | -$949,000 | -$2.40M |
| Income tax | $9,000 | -$8,000 |
| Net income | -$958,000 | -$2.39M |
| EBITDA | -$278,000 | -$1.86M |
| EPS (basic) | -0.01 | -0.01 |
| EPS (diluted) | -0.01 | -0.01 |
| Weighted avg. shares (diluted) | 184.26M | 175.59M |
| Balance sheet | ||
| Cash & equivalents | $278,000 | $454,000 |
| Receivables | $402,000 | $522,000 |
| Inventory | $4.09M | $4.90M |
| Current assets | $5.13M | $6.24M |
| PP&E, net | $344,000 | $399,000 |
| Goodwill | $1.01M | $971,000 |
| Intangibles | $76,000 | $93,000 |
| Total assets | $6.96M | $7.93M |
| Current liabilities | $5.00M | $6.11M |
| Short-term debt | $1.26M | $677,000 |
| Long-term debt | $387,000 | $0 |
| Total debt | $1.65M | $677,000 |
| Total liabilities | $5.49M | $6.13M |
| Shareholders' equity | $1.47M | $1.79M |
| Net debt | $1.37M | $223,000 |
| Shares outstanding | 184.26M | 184.26M |
| Cash flow statement | ||
| Operating cash flow | -$407,000 | -$861,000 |
| Capital expenditure | $109,000 | $18,000 |
| Free cash flow | -$516,000 | -$879,000 |
| Investing cash flow | -$109,000 | -$28,000 |
| Financing cash flow | $337,000 | $32,000 |
| Depreciation & amortization | $192,000 | $334,000 |
| Stock-based compensation | $497,000 | $258,000 |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.